Polyrizon Ltd. (Nasdaq: PLRZ) entered into a non‑binding memorandum of understanding on March 24 2026 with shareholders of Colugo Systems Ltd. to purchase up to 20 % of Colugo’s fully‑diluted shares. The deal values the stake at up to US $6 million, payable either in cash or in Polyrizon shares, with definitive terms to be set in a future agreement. Closing is expected within seven days of satisfying customary conditions, including corporate approvals and a waiver of certain shareholder rights.
The $6 million price for a 20 % stake implies a $30 million valuation for Colugo, a figure that is lower than the $65 million pre‑funding valuation reported when the company raised $8.5 million in June 2025. Colugo’s 2024 revenue of $4 million and its Series A status underscore that the MOU represents a significant early‑stage investment for Polyrizon, which has a strong balance sheet with cash and no long‑term debt but recorded a net loss in fiscal year 2024.
Polyrizon’s core business has been the development of intranasal hydrogel devices, and the company has been exploring ways to diversify its revenue base. The move into the urban‑air‑mobility sector through Colugo’s eVTOL technology offers Polyrizon a new growth avenue and the possibility of cross‑industry synergies, such as leveraging its biomedical expertise in defense‑grade applications for drone payloads and first‑responder support.
Colugo Systems, founded in 2018, is an Israeli developer of advanced electric vertical‑takeoff and landing drones that serve defense and first‑responder customers, including the Israel Defense Forces. The company’s Adaptive Wing Technology enhances stability in windy conditions, positioning it well for both military and civilian urban‑air‑mobility markets. Its recent funding round and modest 2024 revenue highlight a company in early commercialization stages but with strong strategic partnerships.
Investors reacted negatively to the announcement, citing concerns about Polyrizon’s diversification into a capital‑intensive aerospace sector, the valuation discrepancy between the MOU and Colugo’s prior funding round, and the execution risk of integrating a defense‑focused technology firm into a biotech‑centric organization.
The acquisition could broaden Polyrizon’s product portfolio and open new revenue streams, but it also introduces significant strategic and operational challenges. Successful integration will depend on Polyrizon’s ability to manage the technical and regulatory complexities of the eVTOL market while maintaining focus on its core intranasal hydrogel platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.